Loading...
XNAS
ANIP
Market cap2.01bUSD
Oct 27, Last price  
92.86USD
1D
-1.46%
1Q
44.64%
Jan 2017
53.18%
IPO
-66.06%
Name

ANI Pharmaceuticals Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
3.28
EPS
Div Yield, %
Shrs. gr., 5y
9.92%
Rev. gr., 5y
24.36%
Revenues
614m
+26.20%
258,35114,438,621493,0543,780,8291,258,0542,474,237435,1602,300,73630,082,00055,970,00076,322,000128,622,000176,842,000201,576,000206,547,000208,475,000216,136,000316,385,000486,816,000614,376,000
Net income
-19m
L
-9,651,0362,791,273-7,584,435-17,425,178-47,527,768-46,196,216-51,608,504-27,717,739301,00028,747,00015,375,0003,934,000-1,076,00015,494,0006,094,000-22,548,000-42,603,000-47,896,00018,779,000-18,522,000
CFO
64m
-46.19%
-8,297,509-4,996,735739,992-15,535,932-18,430,910-40,097,506-47,870,103-25,283,020-5,484,00022,033,00017,264,00027,472,00039,419,00067,074,00045,631,00015,267,0003,322,000-31,203,000118,959,00064,017,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
IPO date
May 04, 2000
Employees
600
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT